Immunocore News and Activities

View the org chart displaying its 29 main executives

Most searched biographies at Immunocore

• Bahija Jallal, Chief Executive Officer and Director
• Peter Ratcliffe, Non-Executive Director
• Siddharth Kaul, Non-Executive Director

Popular executive movements at Immunocore

• Mohammed Dar, who was Head of Clinical Development and Chief Medical Officer, is promoted to Executive Vice President, Clinical Development and Chief Medical Officer  (posted on January 30 2026).
• David Berman, Head of Research & Development, will leave the company on Feb. 27, 2026  (posted on January 30 2026).
• Tina St. Leger, Chief Human Resources Officer, has left the company  (posted on December 1 2025).

Create your alert
to follow the executive moves at Immunocore.

Immunocore has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Immunocore

• Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine :: Immunocore PLC
• Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial :: Immunocore PLC
• Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021 :: Immunocore PLC
• Immunocore to present at upcoming investor conferences :: Immunocore PLC
• Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
• Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma :: Immunocore PLC
• Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update :: Immunocore PLC
• Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting :: Immunocore
• Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B :: Immunocore
• Immunocore Reports First Quarter 2021 Financial Results :: Immunocore
• View more press releases Close

Social media about Immunocore

• Immunocore on Wikipedia, Google News & Yahoo Finance
• Immunocore on LinkedIn, X (Twitter) & YouTube